Crestone showcased their innovative work at the ESCMID Global conference in Vienna on April 15, 2025. Delivered by Dr. Jon Brus, the highlight of their presentation was CRS3123, a groundbreaking treatment demonstrating high cure rates and low recurrence in addressing toxin positive Clostridiodes difficile infection. Attendees were impressed by the comprehensive data presented and left eager to learn more about the potential impact of CRS3123 on future medical treatments. For those interested in detailed insights, Crestone’s presentation poster offers an in-depth look at their promising research findings.
